<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00156611</url>
  </required_header>
  <id_info>
    <org_study_id>R-1</org_study_id>
    <nct_id>NCT00156611</nct_id>
  </id_info>
  <brief_title>Rio Trial - ReoPro and Peripheral Arterial Intervention to Improve Clinical Outcome in Patients With Peripheral Arterial Disease</brief_title>
  <official_title>ReoPro and Peripheral Arterial Intervention to Improve Clinical Outcome in Patients With Peripheral Arterial Disease - A Randomized Prospective Trial (RIO-Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <brief_summary>
    <textblock>
      The Rio Study is a randomized, double blinded German- Swiss- Austria multi-centre trial on&#xD;
      the efficacy and safety of ReoPro together with interventional recanalization of TASC D&#xD;
      lesions in the SFA and popliteal artery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: The RIO trial is designed to test the efficacy of GP IIb/IIIa blockade on subacute&#xD;
      reocclusions in patients with interventional recanalization of chronic occlusions in the&#xD;
      superficial femoral and popliteal artery.&#xD;
&#xD;
      Methods: A total of 420 patients will be randomly assigned to ReoPro or placebo. Patients&#xD;
      will be eligible for randomisation with occlusions longer than 5 cm. Doppler ultrasound&#xD;
      follow-up will be at 30 days, and after 6, and 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2002</start_date>
  <completion_date>December 2009</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of subacute occlusions within 30 days</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevention of restenosis up to 3 years</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevention of target lesion revascularization</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of the clinical status</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of ABI</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital days</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all secondary outcomes at 30 days, 6 months, one year, and 3 years (telephone contact after 3 years)</measure>
  </secondary_outcome>
  <enrollment>420</enrollment>
  <condition>Arterial Occlusive Diseases</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Balloon Angioplasty</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ReoPro</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of peripheral artery disease with superficial femoral or&#xD;
             popliteal artery occlusion, which mandates PTA or stent administration as first&#xD;
             treatment modality. The history of peripheral artery occlusion has to be at least 6&#xD;
             weeks, and the target vessel occlusion has to be more than 5 centimeters in length.&#xD;
&#xD;
          -  Age between 18 and 90 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute limb ischemia&#xD;
&#xD;
          -  Subacute ischemia with requires thrombolysis as first treatment modality&#xD;
&#xD;
          -  Active bleeding or known bleeding diathesis&#xD;
&#xD;
          -  Known severe hepatic or renal disorder (liver cirrhosis, stage B, C or serum&#xD;
             creatinine &gt; 2.5 mg%)&#xD;
&#xD;
          -  Hyperthyreosis&#xD;
&#xD;
          -  Diabetes mellitus treated with metformin&#xD;
&#xD;
          -  Known heparin induced thrombocytopenia (HIT, type 2)&#xD;
&#xD;
          -  Female sex with childbearing potential&#xD;
&#xD;
          -  Major surgery or trauma in past 6 weeks&#xD;
&#xD;
          -  History of stroke within the previous 2 years, or any stroke with a residual&#xD;
             neurological deficit, or other CNS abnormality (e.g., intracranial neoplasm,&#xD;
             arteriovenous malformation, or aneurysm)&#xD;
&#xD;
          -  Gastrointestinal or genitourinary bleeding of clinical significance within the&#xD;
             previous 6 weeks&#xD;
&#xD;
          -  Administration of oral anticoagulants within the previous 7 days unless prothrombin&#xD;
             time is &lt; 1.2 times control (or international normalized ratio [INR] &lt;1.4), or ongoing&#xD;
             treatment with oral anticoagulants&#xD;
&#xD;
          -  History of bleeding diathesis of platelet count &lt; 100,000/mm3&#xD;
&#xD;
          -  Arteriovenous malformations or aneurysms&#xD;
&#xD;
          -  Severe uncontrolled hypertension (treated sys. BP &gt; 200 mm Hg, diast. BP &gt; 100 mm Hg)&#xD;
&#xD;
          -  Hypertensive or diabetic retinopathy&#xD;
&#xD;
          -  Vasculitis&#xD;
&#xD;
          -  Known autoimmune disorders&#xD;
&#xD;
          -  Patient with aspirin intolerance&#xD;
&#xD;
          -  Contraindication or known allergic reactions to abciximab or murine proteins&#xD;
&#xD;
          -  Co-existent condition associated with a limited life expectancy (e.g., advanced&#xD;
             cancer, end-stage congestive heart failure)&#xD;
&#xD;
          -  Participation in another clinical research study involving the evaluation of another&#xD;
             investigational drug or device within 7 days prior to enrollment&#xD;
&#xD;
          -  Patient who has previously received a GP IIb/IIIa antagonist&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar Tepe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Tuebingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Iris Baumgartner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>September 11, 2006</last_update_submitted>
  <last_update_submitted_qc>September 11, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2006</last_update_posted>
  <keyword>peripheral vascular disease</keyword>
  <keyword>intervention</keyword>
  <keyword>restenosis</keyword>
  <keyword>Age above 18 years</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abciximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

